Current Edition

Adamas

Adamas, Flexion sell for $825M combined as biotech’s dealmaking pace picks up

The two deals announced Monday are attempts by Supernus and Pacira to fold small, revenue-generating drugs into a larger portfolio and boost their prospects. Supernus, …

Continue Reading →